Table 2. Comparison of patients with PLA2R-related and PLA2R-unrelated PMN.
| Positive anti-PLA2R (N = 69) | Negative anti-PLA2R (N = 8) | |||||
|---|---|---|---|---|---|---|
| P50 [P25 ; P75] | ||||||
| n* | n* | p-value | ||||
| Age at diagnosis (years) | 69 | 54.0 [41.4; 63.5] | 8 | 50.0 [39.6; 67.0] | 0.8810 | 1 |
| Follow-up (months) | 69 | 31.0 [19.0; 54.0] | 8 | 40.1[25.8; 63.9] | 0.4661 | 1 |
| At diagnosis | ||||||
| Proteinuria (g/d) | 69 | 7.5 [4.0; 10.0] | 8 | 8.7 [3.6; 14.5] | 0.7144 | 1 |
| eGFR (mL/min) | 69 | 74.0 [57.0; 99.0] | 8 | 87.4 [70.0; 105.5] | 0.2529 | 1 |
| Serum albumin (g/L) | 69 | 20.0 [16.6; 26.0] | 8 | 17.9 [16.4; 23.0] | 0.5440 | 1 |
| End of follow-up | ||||||
| Proteinuria (g/d) | 61 | 0.9 [0.3; 2.8] | 8 | 0.7 [0.3; 1.7] | 0.6710 | 1 |
| eGFR (mL/min | 62 | 70.5 [45.5; 88.0] | 8 | 100.0 [73.0; 160.5] | 0.0374 | 1 |
| Serum albumin (g/L) | 55 | 37.0 [32.0; 40.0] | 8 | 36.0 [33.4; 40.0] | 0.9067 | 1 |
| Stage-4 CKD | 62 | 8 | 0.3383 | 2 | ||
| No | . | 56(81.2) | . | 8 (100) | . | |
| Yes | . | 13 (18.8) | . | 0 (0) | . | |
| Remission | 64 | 8 | 0.2498 | 2 | ||
| No | . | 23 (35.9) | . | 3 (37.5) | . | |
| Yes | . | 41 (64.1) | . | 5 (62.5) | . | |
* number of patients.
Frequencies (percentage) or medians (interquartile range) are shown. Quantitative variables were compared by a Student’s t-test or a Wilcoxon rank-sum test, and categorical variables were compared by a Pearson's Chi-square test or Fisher’s exact test.